Bayram, Fahri
Sonmez, Alper
Kiyici, Sinem
Akbas, Feray
Yetgin, Meral Kucuk
Yazici, Dilek
Cingi, Asim
Sargin, Mehmet
Unal, Seniz
Iseri, Ceren
Mahmutoglu, Fatih Selami
Yumuk, Volkan Demirhan
Funding for this research was provided by:
Novo Nordisk Turkey
Article History
Accepted: 3 November 2023
First Online: 3 January 2024
Compliance with Ethical Standards
:
: Fahri Bayram participated in clinical studies and adboard meetings conducted by Novo Nordisk, Eli Lilly, Abbott, Sanovel, Novartis, Sandoz, Bilim ilaç, Astrazeneca, Pfizer, Ali raif, Econix and Sanofi. Alper Sonmez was involved as the principal investigator in several phase 3 studies conducted by Novo Nordisk, Novartis, Sanofi, participated in adboard meetings performed by Novo Nordisk, Sanofi, AstraZeneca, Eczacıbaşı, Econix, Roche Diagnostics and took grants congress from Bilim Ilaç, Novo Nordisk and AstraZeneca. Volkan Yumuk participated in speakers’ bureaus and advisory board meetings performed by Novo Nordisk. Sinem Kiyici received speaking fees paid to her Institution for Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Servier, Abbott and Novartis. Other authors declare that they have no conflict of interest.
: This article is a review of the published literature. This review article does not contain any studies performed with human or animal subjects by the authors.